{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"41.0","upperLimit":"55.0","value":"48.2"},{"groupId":"OG001","lowerLimit":"14.6","upperLimit":"26.1","value":"20.0"}]}],"title":"6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"36.3","upperLimit":"50.2","value":"43.3"},{"groupId":"OG001","lowerLimit":"3.9","upperLimit":"12.4","value":"7.4"}]}],"title":"12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56.8","upperLimit":"70.0","value":"63.8"},{"groupId":"OG001","lowerLimit":"30.0","upperLimit":"43.3","value":"36.7"}]}],"title":"18 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"50.7","upperLimit":"64.2","value":"57.8"},{"groupId":"OG001","lowerLimit":"20.4","upperLimit":"32.6","value":"26.3"}]}],"title":"24 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.7","upperLimit":"57.5","value":"50.8"},{"groupId":"OG001","lowerLimit":"16.1","upperLimit":"27.6","value":"21.6"}]}],"title":"36 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"36.9","upperLimit":"50.5","value":"43.8"},{"groupId":"OG001","lowerLimit":"12.9","upperLimit":"23.6","value":"17.9"}]}],"title":"48 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32.6","upperLimit":"46.0","value":"39.3"},{"groupId":"OG001","lowerLimit":"12.4","upperLimit":"23.0","value":"17.4"}]}],"title":"60 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.7","upperLimit":"43.9","value":"37.3"},{"groupId":"OG001","lowerLimit":"12.0","upperLimit":"22.5","value":"16.9"}]}],"title":"72 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.5","upperLimit":"42.8","value":"36.2"},{"groupId":"OG001","lowerLimit":"12.0","upperLimit":"22.5","value":"16.9"}]}],"title":"84 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"210"},{"groupId":"OG001","value":"208"}],"units":"Participants"}],"description":"OS rate is calculated as the percentage of participants alive at the indicated timepoints. Data for this endpoint was collected after the primary completion date up until study completion. The OS rate for the 6 month and 12 month timepoints reflect updated data that was collected after the primary completion date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received nivolumab, 3 mg/kg, solution administered Intravenously (IV) every 2 weeks with placebo-matching dacarbazine solution administered IV every 3 weeks, until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion","id":"OG000","title":"Nivolumab, 3 mg/kg + Placebo-matching Dacarbazine"},{"description":"Participants received dacarbazine 1000 mg/m\\^2, solution administered IV every 3 weeks with placebo-matching nivolumab solution administered IV every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion","id":"OG001","title":"Dacarbazine, 1000 mg/m^2 + Placebo-matching Nivolumab"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization to the specified timepoints, up to 84 months","title":"Overall Survival (OS) Rate Extended","type":"POST_HOC","unitOfMeasure":"Percentage of participants"}